NCT05768932 2025-10-15
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
SillaJen, Inc.
Phase 1 Recruiting
SillaJen, Inc.
Massachusetts General Hospital
Amgen
Amgen
Indiana University
Abbott
National Institutes of Health Clinical Center (CC)